EXCLI Journal

EXCLI Journal publishes original research reports, authoritative reviews and case reports of experimental and clinical sciences.

More... Less...

EXCLI Journal (eISSN 1611-2156) is particularly keen to keep a broad view of science and technology, and therefore welcomes papers which bridge disciplines and may not suit the narrow specialism of other journals. Although the general emphasis is on biological sciences, studies from the following fields are explicitly encouraged:

Immunology, toxicology, ergonomics, neurosciences, psychology, occupational medicine, clinical and preclinical studies, drug development, pharmacology, environmental health, chemistry including analytical chemistry, biochemistry, cell biology, genetics, forensic medicine, oncology and cancer research, proteomics, systems biology, hepatology and gastroenterology, aging research, psychiatric research, behavioral sciences.

ORCID - Open Researcher and Contributor ID

2020-12-02

In order to be able to clearly assign our authors, we intend to include the ORCID (Open Researcher and Contributor ID) as a mandatory field for contributors starting in 2021. ORCID is a standard for the identification of contributors in research and scientific publishing. This change is intended to further improve the quality management of EXCLI Journal. For details regarding the ORCID see ORCID – Wikipedia.

In order to speed up the submission process, the ORCID is mandatory as unique identifier for authors from 2021 on.

EXCLI Journal Submission Tool

2019-03-29

EXCLI Journal website allows electronic submissions of manuscripts by users after self-registration as author.

In case of having technical problems, please contact the Editorial Office via email (excli@ifado.de).

We would like to invite you to read the Editorial of the Editor-in-chief.

Vol. 20 (2021)

Published continuously

Published: 2021-01-04

Rivaroxaban versus low-molecular weight heparin plus warfarin prevents portal vein system thrombosis after splenectomy and pericardial devascularization: A randomized clinical trial

Authors: Wei Yao, Yongan Feng, Ting Liu, Wujun Li, Mei Zhang, Yingmin Yao, Shengli Wu

Pages: 537-549

Published: 2021-03-04

Issue: Vol. 20 (2021)

Article - PDF Suppl. Data - XLSX

Angiotensin receptor blocker Losartan inhibits tumor growth of colorectal cancer

Authors: Milad Hashemzehi, Farzad Rahmani, Mahdieh Khoshakhlagh, Amir Avan, Fereshteh Asgharzadeh, Farnaz Barneh, Reyhaneh Moradi-Marjaneh, Atena Soleimani, Hamid Fiuji, Gordon A. Ferns, Mikhail Ryzhikov, Mohieddin Jafari, Majid Khazaei, Seyed Mahdi Hassanian

Pages: 506-521

Published: 2021-03-01

Issue: Vol. 20 (2021)

Article - PDF Suppl. Data - XLSX